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Investigating and managing neonatal
seizures in the UK: an explanatory
sequential mixed methods approach
Lucy Gossling1, James J. P. Alix2, Theocharis Stavroulakis2 and Anthony R. Hart3*
Abstract
Background: Neonatal seizures are difficult to diagnose and, when they are, tradition dictates first line treatment is
phenobarbital. There is little data on how consultants diagnose neonatal seizures, choose when to treat or how
they choose aetiological investigations or drug treatments. The purpose of this study was to assess the variation
across the UK in the management of neonatal seizures and explore paediatricians’ views on their diagnosis and
treatment.
Methods: An explanatory sequential mixed methods approach was used (QUAN→QUAL) with equal waiting
between stages. We collected quantitative data from neonatology staff and paediatric neurologists using a
questionnaire sent to neonatal units and via emails from the British Paediatric Neurology Association. We asked for
copies of neonatal unit guidelines on the management of seizures. The data from questionnaires was used to
identify16 consultants using semi-structured interviews. Thematic analysis was used to interpret qualitative data,
which was triangulated with quantitative questionnaire data.
Results: One hundred questionnaires were returned: 47.7% thought levetiracetam was as, or equally, effective as
phenobarbital; 9.2% thought it was less effective. 79.6% of clinicians had seen no side effects in neonates with
levetiracetam. 97.8% of unit guidelines recommended phenobarbital first line, with wide variation in subsequent drug
choice, aetiological investigations, and advice on when to start treatment. Thematic analysis revealed three themes:
‘Managing uncertainty with neonatal seizures’, ‘Moving practice forward’ and ‘Multidisciplinary team working’. Consultants
noted collecting evidence on anti-convulsant drugs in neonates is problematic, and recommended a number of
solutions, including collaboration to reach consensus guidelines, to reduce diagnostic and management uncertainty.
Conclusions: There is wide variation in the management of neonatal seizures and clinicians face many uncertainties.
Our data has helped reveal some of the reasons for current practice and decision making. Suggestions to improve
certainty include: educational initiatives to improve the ability of neonatal staff to describe suspicious events, greater
use of video, closer working between neonatologists and neurologists, further research, and a national discussion to
reach a consensus on a standardised approach to managing neonatal epileptic seizures.
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Background
Seizures are common in the neonatal period because of
the relative excitability of the neonatal brain and high risk
of pathologies leading to acute symptomatic seizures [1–
7]. The true incidence of neonatal seizures is unknown,
but proposed rates are 3/1000 term live births and be-
tween 132/1000 preterm neonates [8] One reason why in-
cidence figures may be inaccurate is because neonatal
seizures are difficult to diagnose: multiple studies using
EEG have shown that most neonatal seizures have no clin-
ical features at all (electrographic seizures) [9–14], and the
accurate differentiation of epileptic seizures from non-
epileptic events based on clinical skills alone is poor [9,
10, 15, 16]. For example, one study of term neonates
showed only 34% of neonatal seizures having had clinical
features and 73% of suspected seizures having had no epi-
leptiform discharges associated with them on electroen-
cephalography (EEG) [9]. As a result, neurophysiological
techniques are used to support diagnosis, but the gold
standard, continuous video EEG, is not available in all UK
neonatal units, and the logistics of siting leads, checking
recording quality, starting the monitor, and interpreting
the EEG, 24 h a day, 7 days a week are enormous. Instead,
amplitude integrated EEG (aEEG) is used routinely on
neonatal units, particularly in term babies with hypoxic is-
chaemic encephalopathy (HIE) [17, 18], and can detect 1/
3 of single seizures and 2/3 of repetitive seizures, missing
those that are brief or distant from the EEG leads [17,
19]. Having two channels and the single lead EEG trace
available for review on the aEEG monitor improves
seizure detection rates [19–21].
Once a diagnosis of neonatal seizures has been made,
health care professionals have to decide what the likely
aetiologies are, which investigations to perform, whether
to treat the seizures and, if so, with what drugs. One
particular conundrum is whether to treat electrographic
seizures. There is little published data on how health
care professionals view this, but 36.7% of US health care
professionals presented with a theoretical case treated
isolated electrical seizures in neonates with mild HIE,
and 74.6% treated recurrent electrographic seizures in
moderate HIE. Variation was also noted in how long
neonatal seizures had to last before treatment was initi-
ated and whether the baby was given a single dose or
started on regular maintenance doses [22].
In the UK, there is no universally accepted guideline on
the management of neonatal seizures, although the World
Health Organisation recommends electrographic seizures
should be treated in the same way as clinical seizures [23].
Little data exists on the variation in UK management of
neonatal seizures, nor the reasons for any observed vari-
ation. Once treatment is commenced, Phenobarbital is rec-
ommended as first line treatment in the UK [5], although
little data exists on health care professionals’ views of its
effectiveness, what their choice of second line treatment is,
nor how they choose when to treat and with what drug.
Our aims were the answer the following questions:
 What factors influence health care professionals
when diagnosing neonatal seizures?
 How many health care professionals utilise aEEG
when diagnosing neonatal seizures and what were
health care professionals’ views of its use?
 How many health care professionals routinely
treated clinical and electrographic seizures and what
factors lead them to treat a neonate with anti-
convulsant drugs?
 What anti-convulsant drugs are health care
professionals using to treat neonatal epileptic
seizures and in what order?
 Why health care professionals choose the drugs they
do, and what are their attitudes on their
effectiveness and side effects?
 What steps or evidence are needed to improve
confidence in diagnosis and treatment of neoantal
seizures,and to reduce variation in care between
health care professionals when treating neonatal
epileptic seizures?
Methods
The mixed nature of our research questions (containing
interconnected quantitative and qualitative features)
required the use of a study design integrating both quan-
titative and qualitative methodologies [24]. We adopted
an explanatory sequential mixed methods approach in
two distinct phases (QUAN→QUAL) [25]. We con-
ducted a questionnaire survey (Phase I) to examine
health care professionals’ practice when diagnosing and
treating neonatal epileptic seizures, followed by qualita-
tive interviews (Phase II) to explore the reasoning for
any variation noted. Equal weighting was given to both
aspects of this approach.
Phase I
We designed a questionnaire in paper and electronic
versions on health care professionals’ views of neonatal
seizures (Additional file 1, available online) based on the
published findings of variation in care in the US and
Sweden [22, 26] and the authors’ observations of UK prac-
tice. We included specific questions about levetiracetam be-
cause our experience is levetiracetam is being increasingly
used in clinical practice and recommendations in the UK
have suggested it could be incorporated into guidelines [5].
196 Neonatal units were identified from a national trans-
port group website (ukntg.net/uk-neonatal-units), which
lists all UK neonatal units. The clinical lead of each unit
was asked if they and other members of their staff would
complete the questionnaire. Members of the British
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Paediatric Neurology Association (BPNA) were asked to
complete the electronic version of the questionnaire via
a monthly e-newsletter. Frequencies and percentages of
answers were calculated and copies of seizure guidelines
were requested.
Intermediate stage - connection of the two phases. The
last question of the questionnaire asked if responders were
willing to attend a qualitative interview to explore their
views in more depth. From the list of volunteers, we used
a purposeful sampling approach to ensure we obtained a
range of views from different specialities, geographical
areas, and years of experience. As such, the identities, spe-
cialisms and year of registration on the Specialist Register
of the General Medical Council were available to us.
Adhering to the explanatory sequential mixed methods
design, the results of the questionnaire guided the choice
of questions in the interview schedule, with a focus specif-
ically on attitudes to the diagnosis of neonatal epileptic
seizures and the timing and choice of anti-convulsant
drug treatment.
Phase II
Written informed consent was obtained from interview
participants. Data was collected with semi-structured in-
terviews conducted by a single member of the research
team (LG) at a time and location of the participants’
choice. The topic guide for the interviews is available
online (Additional file 2). Interviews were digitally re-
corded, transcribed verbatim and checked for accuracy.
Thematic analysis was performed as per Braun and
Clarke (2006) [27]. This included familiarisation of data,
initial coding of all data using an inductive approach by
two researchers (LG and ARH), review of initial codes,
agreement on a coding structure for the whole dataset,
and identification of a thematic structure to determine
main and subthemes. Themes were developed using an
iterative process to capture all range of views. We ceased
recruiting for interviews when we reached thematic
saturation, mindful of published recommendations on
cohort size [28–30]. NVivo for Mac version 12 (QSR
International PTY Ltd., 2018) was used to aid data ana-
lysis. Finally, the results of the quantitative and qualita-
tive phases were integrated to find explanations for any
observed variations in practice. This is presented in the
discussion section of this manuscript.
Ethical approval was obtained from the University of
Sheffield (Reference Number 017700).
Results
Phase I: quantitative data on neonatal seizures
One hundred questionnaires were returned: 81 consul-
tants, 7 nursing staff, 1 trainee, and 11 unknown staff
members. Thirty-three worked in neonatal intensive care
(Level 3) units, 45 in local neonatal (level 2 or 1) units
or paediatric departments, and 22 in paediatric neur-
ology. The 78 responders who worked in neonatal units
represented 68 different units, which is 34.7% of all UK
units caring for neonates. The BPNA includes members
from many specialities, including neurophysiologists, dis-
ability paediatricians and allied health care professionals,
around the world, all of whom will have the option of
receiving the e-newsletter. Reporting response rates for
this distribution list is not appropriate as the project was
not relevant to all subscribers. There are 120 consultant
paediatric neurologists in the UK, so 22 responses repre-
sent 18.3% of this total population, although not all of
these consultants are involved in the care of neonates
with seizures. All answers were treated equally, irre-
spective of the degree of seniority or specialism of the
respondent.
The results of our questionnaire are summarised in
Table 1. 34.0% of responders routinely treated electro-
graphic seizures, 49.0% treated them sometimes, and
17.0% reported they did not treat electrical seizures.
53.0% thought that electrical seizures were as important
as clinical seizures, compared to 16.0% who thought they
were less important. When asked whether seizures cause
harm to the brain independent of the underlying aeti-
ology, 62.0% thought they did and 15.0% did not. The
frequency of replies for neonatologists and neurologists,
as well as for only the responders identifying themselves
as consultants, is shown separately in Table 1.
73/94 (77.7%) responders’ units had a guideline for the
management of neonatal seizures. 90 (95.7%) responders
indicated their guideline’s first line anti-convulsant
medication: 83/90 (92.2%) used phenobarbital, 1 (1.1%)
phenytoin, 2 (2.2%) used either phenobarbital or pheny-
toin, 1 (1.1%) levetiracetam, and 3 (3.4%) either pheno-
barbital or levetiracetam. In addition to phenobarbital, a
range of other drugs were used to treat neonatal seizures
(Table 2).
29/94 (30.1%) responders reported that phenobarbital
was very effective at treating neonatal seizures, 65 (69.2%)
said that it stopped some seizures but not all. No re-
sponder thought that phenobarbital was ineffective.
65 (73.3%) responders had experience of using levetirac-
etam, and their views on its effectiveness were similar to
phenobarbital (Table 1). When asked to directly compare
levetiracetam to phenobarbital, 14/65 (21.5%) thought
levetiracetam was more effective, 17 (26.2%) equally effect-
ive, 6 (9.2%) less effective, and 28 (43.1%) did not know.
Reported side effects seen with levetiracetam were:
 None 39/49 (79.6%)
 Irritability, hyperkinetic movements / jitteriness 5
(10.2%)
 Sleepiness 3 (6.1%)
 Electrolyte disturbance 2 (4.1%)
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Table 1 Frequency of responses to questions in our questionnaire separated by primary type of unit in which responders work
Question Responders
All
responders
Working
predominately
in a NICU -
Level 3
Working in
paediatrics, Level 2
unit, or interest in
epilepsy
Working predominately in
paediatric neurology /
neurodisability unit
All
Consultant
Responders
Do you treat clinical seizures
(i.e. where there is no available
aEEG / EEG data to confirm
abnormal movements are
seizures?
Yes 65/100
(65.0%)
18/33 (54.6%) 38/45 (84.4%) 9/22 (40.9%) 54/81
(66.7%)
No 9/100
(9.0%)
4/33 (12.1%) 3/45 (6.7%) 2/22 (9.1%) 5/81 (6.1%)
Sometimes 26/100
(26.0%)
11/33 (33.3%) 4/45 (8.9%) 11/22 (50.0%) 22/81
(27.2%)
Do you treat electrical seizures
(i.e. diagnosed on aEEG/EEG)
which do not have any clinical
features to see?
Yes 34/100
(34.0%)
14/33 (42.4%) 15/45 (33.3%) 5/22 (22.7%) 27/81
(33.3%)
No 17/100
(17.0%)
1/33 (3.0%) 15/45 (33.3%) 1/22 (4.5%) 11/81
(13.6%)
Sometimes 49/100
(49.0%)
18/33 (54.6%) 15/45 (33.3%) 16/22 (72.7%) 43/81
(53.1%)
Do you think electrical
seizures are:
As important as
clinical seizures
53/100
(53.0%)
17/33 (51.5%) 25/45 (55.6%) 11/22 (50.0%) 43/81
(53.1%)
More important
than clinical
seizures
9/100
(9.0%)
2/33 (6.1%) 4/45 (8.9%) 3/22 (13.6%) 6/81 (7.4%)
Less important
than clinical
seizures
16/100
(16.0%)
6/33 (18.2%) 5/45 (11.1%) 5/22 (22.8%) 14/81
(17.3%)
I don’t know 22/100
(22.0%)
8/33 (24.2%) 11/45 (24.4%) 3/22 (13.6%) 18/81
(22.2%)
Do you think seizures themselves
cause harm to the brain/
development (i.e. not related to
apnoea/hypoxia and independent
of the underlying cause)?
Yes 62/100
(62.0%)
24/33 (72.7%) 27/45 (60.0%) 11/22 (50.0%) 53/81
(65.4%)
No 15/100
(15.0%)
3/33 (9.1%) 9/45 (20.0%) 3/22 (13.6%) 12/81
(14.8%)
I don’t know 23/100
(23.0%)
6/33 (18.2%) 9/45 (20.0%) 8/22 (36.4%) 16/81
(19.8%)
Do you routinely use cerebral
function monitoring (aEEG) for
monitoring neonates at high risk
of seizures or those having
recurrent seizures?
We use it in all
neonates at risk
of seizures
44/94
(46.8%)
20/31 (64.5%) 12/43 (28.0%) 12/20 (60.0%) 39/78
(50.0%)
We use it only in
those with HIE
10/94
(10.6%)
5/31 (16.1%) 5/43 (11.6%) 0/20 (0.0%) 9/78
(11.5%)
We use it in
selected cases,
HIE and non-HIE
20/94
(21.3%)
5/31 (16.1%) 8/43 (18.6%) 7/20 (35.0%) 14/78
(18.0%)
We don’t use it
at all
19/94
(20.2%)
1/31 (3.3%) 17/43 (39.5%) 1/20 (5.0%) 16/78
(20.5%)
I don’t know 1/94
(1.1%)
0/31 (0%) 1/43 (2.3%) 0/20 (0%) 0/78 (0%)
With reference to Phenobarbital,
do you think it is …
Very effective 29/94
(30.9%)
6/31 (19.4%) 16/43 (37.2%) 7/20 (35.0%) 25/78
(32.1%)
Stops some
seizures but not
all
65/94
(69.1%)
25/31 (80.6%) 27/43 (62.8%) 13/20 (65.0%) 53/78
(67.9%)
Not at all
effective
0/94 (0%) 0/31 (0%) 0/43 (0%) 0/20 (0%) 0/78 (0%)
Have you tried Levetiracetam for
treatment of neonatal seizures?
Yes 65/94
(69.1%)
26/31 (83.9%) 19/43 (44.2%) 20/20 (100%) 59/78
(75.6%)
No 29/94
(30.9%)
5/31 (16.1%) 24/43 (55.8%) 0/20 (0%) 19/78
(24.4%)
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 Respiratory depression 1 (2.0%)
We received 18 different neonatal unit or network
guidelines. Network guidelines included a number of cen-
tres of different levels, some of which will and will not
have on-site access to aEEG and EEG. Variation was noted
in recommended aetiological investigations for neonatal
seizures (Fig. 1), guidance on when to treat seizures, and
choice of anti-convulsant drugs if phenobarbital was inef-
fective (Fig. 2). Thirty-eight responders agreed to consider
being involved in Phase 2.
Phase II: qualitative data on the diagnosis and treatment
of neonatal seizures
Sixteen consultants were interviewed: 5 Level 3 Neonatol-
ogists, 7 Paediatric Neurologists, 4 Paediatricians at a local
neonatal (level 2) unit / district general hospital: 3 with ex-
pertise in neonatology and 1 in epilepsy. Eleven were male
and 5 female. We chose interviewees from different geo-
graphic regions to ensure we were not finding views
linked only to local practice. The mean years of consultant
experience was 11 years and 2months (range 2months to
28 years). The length of interviews ranged from 45min to
1 h 40min, with a median length of 1 h 10min. Pseudo-
nyms are used to maintain anonymity.
Three themes emerged from the study (Fig. 3):
 Managing uncertainty with neonatal seizures
 Moving practice forward
 Multidisciplinary team working.
Managing uncertainty associated with neonatal seizures
This theme explored the uncertainty clinicians face when
deciding whether a neonate is having seizures and, if so,
how to treat them. It contained the following subthemes:
 weighing up the evidence for a diagnosis of seizures
 deciding when to treat
 choosing anti-convulsant medication.
Table 1 Frequency of responses to questions in our questionnaire separated by primary type of unit in which responders work
(Continued)
Question Responders
All
responders
Working
predominately
in a NICU -
Level 3
Working in
paediatrics, Level 2
unit, or interest in
epilepsy
Working predominately in
paediatric neurology /
neurodisability unit
All
Consultant
Responders
Do you think Levetiracetam
(Keppra) is …
Very effective 21/65
(32.3%)
8/26 (30.8%) 9/19 (47.4%) 4/20 (20.0%) 19/59
(32.2%)
Stops some
seizures but not
all
44/65
(67.7%)
18/26 (69.2%) 10/19 (52.6%) 16/20 (80.0%) 40/59
(67.8%)
Not at all
effective
0/65 (0%) 0/26 (0%) 0/19 (0%) 0/20 (0%) 0/59 (0%)
Compared to Phenobarbital,
do you think Levetiracetam is
Better than
phenobarbital
14/65
(21.5%)
7/26 (26.9%) 3/19 (15.8%) 4/20 (20.0%) 13/59
(22.0%)
As good as
phenobarbital
17/65
(26.2%)
3/26 (11.5%) 9/19 (47.4%) 5/20 (25.0%) 14/59
(23.7%)
Less good than
phenobarbital
6/65
(9.2%)
1/26 (3.9%) 1/19 (5.2%) 4/20 (20.0%) 6/59
(10.2%)
I don’t know 28/65
(43.1%)
15/26 (57.7%) 6/19 (31.6%) 7/20 (35.0%) 26/59
(44.1%)
Table 2 Other anti-convulsant drugs responders reported they
used
Drug Proportion of responders saying
they had experience of using in
neonates
(n = 94)
Phenytoin 74 (78.2%)
Levetiracetam 65 (73.3%)
Midazolam 62 (66.0%)
Lorazepam 18 (19.2%)
Paraldehyde 13 (13.8%)
Lignocaine 15 (16.0%)
Vitamins / pyridoxine 12 (13.3%)
Diazepam 5 (5.3%)
Clonazepam 4 (4.4%)
Topiramate 3 (3.3%)
Carbamazepine 3 (3.3%)
Sodium valproate 1 (1.1%)
Vigabatrin 1 (1.1%)
Prednisolone 1 (1.1%)
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Fig. 1 Investigations recommended on received guidelines to determine the aetiology of neonatal seizures: Red – 1st line; blue – 2nd line or
only to be requested under certain circumstances; orange – 3rd line. Guideline from centre G did not attempt to recommend investigations.
Abbreviations: FBC – full blood count; U&E – urea and electrolytes; LFT – liver function tests; CK – creatine kinase, TFT – thyroid function test; AA
– amino acids; VLCFA – very long chain fatty acids; CRP – C-reactive protein; OA – organic acids; AASA – alpha amino adipic semialdehyde; MRI –
magnetic resonance imaging; aEEG – amplitude integrated electroencephalography; EEG – electroencephalography
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Fig. 2 Information from received guidelines on when to treat neonatal seizures, and recommended treatments and doses. Red – 1st line; blue -
2nd line; orange – 3rd line; pink – 4th line; green – 5th line; turquoise – 6th line; grey – 7th line; black – 8th line; purple – 9th line; yellow – to be
tried at the discretion of the consultant at any time. Abbreviations: D – diazepam; L – lorazepam; mg – milligram; mcg – microgram; kg –
kilogram; h – hour; d- day, BD – twice a day; TDS – three times a day
Fig. 3 Summary of results of thematic analysis from qualitative interview study
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Weighing up the evidence for a diagnosis of seizures
Consultants found diagnosing neonatal seizures difficult,
and consultants reported uncertainty increases with ex-
perience and seniority because of a greater awareness of
differential diagnoses. Consultants were suspicious of
diagnoses made by junior staff, particularly doctors in
training, who were seen as over-diagnosing seizures and
being too influenced by nursing staff. Lucy, a neonatolo-
gist, explained:
“You’re much more persuaded by the nursing staff
as a junior doctor cos you totally trust them … . So,
if they said to you ‘that baby had a seizure’ you
probably would have been much more likely to go
along”.
When a consultant was sceptical about a diagnosis,
they wanted descriptions of the events to confirm the
diagnosis of a seizure was correct. Tim noted a cultural
difference in how junior doctors obtain descriptions of
neonatal events to older children and adolescents:
“If you are sitting in an outpatient clinic and the GP
[General Practitioner] has made a referral that this
patient has had episodes of funny movements and they
are worried they might be seizures, the thing that you
put great emphasis on is the history. You listen to
what the parent has to say, they may have taken a
video of it on their phone.... Flip to a post-natal ward,
nobody believes a parent - ever. So, if a parent presents
their baby having funny movements, a midwife will
not believe anything until she has seen it for herself.
Bizarrely, the doctors, who if they were in paediatrics
would have no problem going on the maternal story,
will not believe the maternal story until they have seen
it for themselves. And you have to ask yourself ‘what is
it that so changes their attitude to being in paediatrics
and being in neonates?’”
The consultant paediatric neurologists particularly
lamented the quality of the descriptions they re-
ceived and noted nearly all seizures were described
as “tonic clonic”. Bella, a Consultant Paediatric Neur-
ologist, noted:
“We will be told that they’re fitting and when you ask
for a description it is often hard to get specific detail
about that. So, it sometimes is hard to know whether
what they are describing is a true seizure or whether it
is an involuntary movement or some other, um,
neurological phenomenon.”
Christopher noted that junior colleagues gave him the
seizure type rather than a description:
“I think it’s difficult with medical colleagues, isn’t it? If
they say ‘it’s clonic’, I probably wouldn’t quiz them in
great detail about whether their limbs are stiff and
consistent, you know what I mean? … I would
probably be a bit more inclined to accept at face value
their interpretation of the seizure type, but of course
that might incorrect.”
One way to improve diagnosis suggested by both
neonatologists and neurologists was to video events on
smartphones, although one interviewee was worried
doing this on the neonatal unit might imply care was
suboptimal: “It’s obviously an attractive idea I just feel it
makes you look a little bit sort of silly if you’re in inten-
sive care unit and say ‘oh can you video as well’, but you
know perhaps I shouldn’t be, perhaps it’s my own pride”.
EEG or aEEG were also used to improve diagnostic
certainty. Neurologists preferred to use a combination of
history and EEG with video but were concerned about
the quality of neonatal EEG recordings and reporting,
and noted some neurophysiologists lacked confidence
and competence to interpret neonatal EEG. On the other
hand, neonatologists struggled with the accessibility of
EEG, as Fiona explained:
“The unit has got semi-direct access to an EEG
machine and even that sometimes takes us a day. …
And then in other units, I have only just learned this,
because we were discussing the network seizure
guideline, that they didn’t have access to EEG
machines at all. I was a bit shocked actually.”
Instead, neonatologists saw aEEG as a pragmatic solu-
tion for improving diagnostic certainty, but acknowledged
it was “not the answer to your prayers” because it missed
brief seizures and those distant from the leads. Consul-
tants highlighted a number of training needs including:
how to site the leads, set up the monitor, and interpret the
trace. Neonatologists correctly perceived neurologists
were wary of aEEG: neurologists thought its introduction
had “jumped the gun” before the optimal way to manage
neonatal seizures was understood. A proportion of the
neurologists’ scepticism reflected their own lack of confi-
dence in interpreting aEEG, as Suresh explained:
“I’m not particularly competent or confident from my
perspective. I don’t, we never used it in my training.”
Both neurologists and neonatologists suggested time-
locked video alongside aEEG would improve diagnosis,
but such monitors were not readily available.
Deciding when to treat neonatal seizures Once a seiz-
ure was diagnosed, consultants weighed-up the risks and
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benefits of medication. The aetiology of seizures was
critical: seizures related to a severe neonatal epilepsy
syndrome, structural brain abnormalities, or metabolic
conditions were not treated as aggressively. Where the
seizures were caused by HIE, the following factors were
important when deciding whether to treat:
 The natural history of the seizures, i.e. acute
symptomatic seizures “burn out”
 Whether the seizures were accompanied by
significant clinical features like profound apnoea /
desaturation
 Frequency and duration
 Whether electrical seizures were as important as
clinical seizures
 Whether seizures cause harm independent of the
underlying aetiology
 The side effects of the anti-convulsant drugs
 Parental or nursing staff anxiety.
There were clear benefits of treating seizures with se-
vere clinical features. For clinical seizures with milder
manifestations or electrical seizures, most consultants
made a judgement on a “case-by-case basis” about
whether the frequency and duration were sufficient to
warrant treatment, agreeing to treat “a high burden of
seizure activity”. Interviewees explained there was no
agreement about what a high burden of seizure activitiy
meant and scientific evidence was not a part of clinician
thinking, with variation seen even within single units, as
Fiona explained:
“I have not got any set rules. Within the unit we really
have not got any set rules. Um, we’ve all got slightly
different thresholds from when we would treat, really
depending on the clinical scenario.”
A number of neonatologists held onto algorithms they
were taught as trainees, as Tim explained:
“We used to have the Levene rule of 3. So, you needed
to have 3 seizures or a seizure lasting more than 3
minutes, before we would treat, okay, I think that was
in an hour”.
A proportion of neonatologists aggressively treated
both electrical seizures and clinical seizures with minor
manifestations, driven by a belief that all seizures directly
contributed the “burden of brain injury”. Neurologists
were more comfortable not treating electrical seizures,
as Bella explained:
“The question is, ‘Is it better to have a more normal
background EEG if you can, but a child that’s really
flat and moribund because you’ve got them on 5, 6
drugs?’. … in certainly my training, it was very much
‘treat the child or the infant, not the EEG’”.
Suresh summed up the consultant neurologists’ thoughts
by saying:
“the link between seizure frequency and severity and
brain development is weak and difficult. We don’t
really understand it, why do some children do very
badly with their development and others do well.”
Consultants of all specialities also considered the risk of
anti-convulsants affecting neuro-developmental outcome
themselves. Most thought adverse neuro-developmental
outcome was more likely to occur after long-term admin-
istration of anti-convulsants, rather than isolated doses,
and were sceptical about relying on animal study data.
Some consultants were concerned the sedative properties
of traditional drugs made a neonate’s “neurological exam-
ination probably seem more abnormal than it may be”,
making “their progress or lack of it” impossible to deter-
mine and inpatient stays longer. Ben noted:
“The problem with the phenobarbitone yes, so the half
life time was 5-7 days. So, we treat HIE babies with
phenobarb, maybe for electrical seizures, and then you
have to tell the parents ‘Well, because we had to treat
with this, it will take the baby at least 3 days to wake
up and to come back to normal and that is not be-
cause the brain is damaged’.”
If initial drugs are ineffective, consultants appraised
the balance between the benefits of treatments and side
effects again, but many consultants avoided multiple
drugs because of sedative side effects and the need for
ventilatory support. If several drugs did not work, con-
sultants reached a “plateau” where they accepted sei-
zures rather than using further drugs.
The final driver that consultants perceived pushed
them towards deciding to treat neonatal seizures was
parental or staff anxiety. They wanted to “feel like we’re
doing something”, although this could lead to them
“treating the parents and the nurses rather than the
baby”. As Lucy explained:
“I think there’s sometimes pressure, I mean that in
a nice way, not in you know not a bad way at all,
from nursing staff to get to get rid of all funny
movements.”
Choosing anti-convulsant medication Phenobarbital
was the first line drug for all of our interviewees because
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of tradition, familiarity, and local or network guidelines,
as Ben explained:
“Neonatology people are quite traditional in what they
use … you will find that most people stick to what they
know, what they use, and therefore they will always
follow the guidelines.”
Neonatologists thought it was “inappropriate” to devi-
ate unilaterally from the guideline and thought they
would face questions or criticisms from nursing staff or
colleagues if they did. This reduced their experience of
alternative treatments, because seizures that had not
responded to initial anti-convulsant drugs were more
likely to be refractory to other medications too.
Neurologists reported they were not often involved in
initiating treatments for neonatal seizures. When they
were involved in treatment decisions, neurologists were
less protocol-driven, would tailor drug choice to under-
lying aetiology, and were more comfortable with a wider
repertoire of drugs than neonatologists. Neurologists
liked levetiracetam, having had experience of its use in
older children, and thought it was effective at treating
neonatal seizures. John was an exception, noting “We
use quite a lot and I, the more I have used it, I think it
might not be working as good as I expected it to work. …
Maybe the dose is not right”. Few side effects were noted
with levetiracetam in neonates, and it was described by
neurologists as “clean” and “forgiving”. Overall, neurolo-
gists couldn’t “see a reason why it can’t be first line.”
Moving practice forward
This theme examined how practice could be improved
in the future. There were three main suggestions: educa-
tion; further research studies; and consensus agreement
on national guidelines.
Training for medical trainees, consultants and nurses
on the neurological assessment of the neonate, patterns
of movements likely to be seizures, differential diagno-
ses, how to set up and interpret aEEG, the use of EEG,
and aetiological investigations was reported to be “the
most important thing” to be doing now. In comparison,
research was seen as more important for long-term im-
provements. Consultants formed two groups: ‘purists’
insisted on evidence from randomised controlled trials
on drug effectiveness, side effects, how aggressively to
treat seizures, whether to treat electrical seizures, and
the long-term developmental effects before they would
change guidelines. The second group were ‘Pragmatists’,
who accepted organising formal studies was problematic,
expensive, and would take a long time. They suggested
drawing on the cumulative experience of clinicians to
form a national consensus guideline. Ben explained:
“It’s not research, it’s just identifying ‘what is
happening?’ and ‘What are people doing and why are
they doing it?’ This is exactly what you want to
understand, and you need to understand why people
feel safe or what is needed to make them feel safe …
it’s not about research knowing why levetiracetam
might be better, but if you can just point out the new
doctrine has same efficacy but they wake up earlier, so
the parents are more pleased about whatever this is
about it, and then you can set up a new strategy
including all these aspects … I think that this is ending
up may be in a national survey and a guideline and
that might be influential … Neonatologists are not
brave. It’s not like neurosurgeons: you give them a new
toy and they will stick the toy in the head of a
patient.”
Multidisciplinary team working
This theme described working relationship between spe-
cialities. Neonatologists worked in networks with other
centres, but only a small number worked regularly with
neurologists. When they did, they gained “more insight
maybe into seizures, and how, what we should treat”.
Neurologists were not routinely called when seizures
were first treated and were only consulted in a child who
was not responding as the neonatologists expected. Neu-
rologists thought they could be consulted more frequently
and saw positives in collaboration: they felt deskilled when
they were only consulted for complex cases, leading to
“book based” advice, and wanted to see a wider spectrum
of conditions. They thought their experience on a wide
range of neurological conditions, drugs, and developmen-
tal outcome would be useful for neonatologists and re-
ported cross fertilisation of “information from conferences”
and experience would promote creativity. One neurologist
suggested the neonatologists have wide experience of a
limited number of conditions and, without formal neur-
ology training, have a blinkered view: “I think sometimes
people don’t know what they don’t know”.
Discussion
Consultants face many challenges when considering the
cause of abnormal neonatal movements and need to
reach a “point of certainty” before making a diagnosis of
a seizure. A number of factors increase this degree of
certainty, the main one being the ability to witness the
events themselves. This is a challenge because consul-
tants are typically called to review a baby after the event
has stopped and find that junior medical or nursing staff
give bland “seizure types”, which are often wrong, in-
stead of detailed descriptions of what happened. This
may be a result of a cultural difference between neonat-
ology and general paediatrics / neurology, where ictal
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phenomenology and the use of videos is an essential part
of the diagnostic process. As a result, consultants find an
abnormal neonatal event has often been attributed and
treated as a seizure before they attend, without consider-
ation of differential diagnoses. This, and the traditional
classifications of seizures types in neonates, as described
by Volpe [31], may explain to some extent why over-
diagnosis of neonatal seizures is common and why consul-
tants think diagnostic accuracy could be improved without
neurophysiology support using a thorough approach to
diagnosis. Even if it this is true, it would not improve the
diagnosis rates of the large majority of neonatal seizures,
which have either subtle, brief or no clinical features at all
[9], supporting calls for neonatal seizures to be reliant on
neurophysiological techniques [15, 32, 33].
Where neurophysiological techniques are used in neo-
nates, consultants disagree on which method is the most
suitable. Nearly all tertiary neonatology services rou-
tinely use aEEG, compared to 39.5% from secondary
level neonatal and paediatric units. Although we did not
plan our interview schedule to discuss the use of aEEG
in secondary level units, one paediatrician in a district
general hospital was actively seeking to purchase a
monitor, whilst another thought it was inappropriate for
their unit to have one because their staff lacked training
and expertise in its use. Neonatal and neurology net-
works need to decide whether they support the intro-
duction of aEEG into secondary level units and general
paediatric wards. From a practical perspective, it is feas-
ible with appropriate training and support [34], but
others argue the National Institute of Clinical Excellence
recommend young children with seizures should be
reviewed by a paediatric neurologist [35], and aEEG may
delay access to specialist opinion. Away from secondary
level centres, neurologists prefer EEG and are wary of
aEEG, thinking neonatologists place undue reliance on
its ability to detect neonatal seizures. Some of this nega-
tivity may reflect neurologists’ own lack of training and
confidence in using aEEG. We should also be aware that,
whilst EEG is seen as the gold standard investigation for
the diagnosis of neonatal seizures, it is only as good as
the neurophysiologist interpreting it, and differences in
opinions on what EEG findings are neonatal seizures will
exist in practice [36, 37]. In contrast, neonatologists rec-
ognise the value of EEG but do not have the same ease
of access as neurologists, taking a pragmatic view that
aEEG is a flawed tool, but one that allows for monitoring
over longer periods of time than EEG, is more likely to
capture recurrent seizures, is accessible, relatively easy to
interpret, and better than clinical diagnosis on its own.
A further area of controversy relates to whether elec-
trographic seizures are important or not. Tertiary neona-
tologists are twice as likely as neurology consultants to
treat all electrographic seizures. This observation cannot
occur because neurologists think electrographic seizures
are unimportant; in fact, twice as many neurologists as
neonatologists reported in our questionnaire that elec-
trical seizures were more important than seizures with
clinical features. Instead, it probably reflects whether
consultants think seizures cause additional harm to the
brain independent of the underlying aetiology: almost
three quarters of neonatal staff answering our question-
naire thought seizures cause harm to the developing
brain, compared to half of neurology staff, and neonatal
interviewees indicated this was a major driver for them
to treat electrical seizures aggressively.
The published evidence on whether clinical or elec-
trical seizures causes harm in neonates is unclear: animal
studies are contradictory about whether induced seizures
are associated with brain injury without hypoxia-
ischaemia [38, 39], and one study shows seizures and
hypoxia-ischaemia in rats combine to produce worse
brain injury [39]. In neonates with HIE, near infrared
spectroscopy demonstrates increased cerebral oxygen-
ation, blood flow and oxygen metabolism during seizures
[40, 41], and MR spectroscopy results are affected by
seizure severity [42]. Evidence on whether seizures are
associated with poor outcome is similarly contradictory.
Small studies show that treating clinical and electrical
seizures using aEEG and / or EEG is associated with im-
proved MRI scores at discharge compared to treating
only clinically suspected seizures [43, 44]. Whilst there
no statistically significant difference in developmental as-
sessment is noted between groups at 18-24 months of
age, one study shows a trend to better outcomes when
neurophysiological techniques were used and electro-
graphic seizures treated [44]. Another study found the
presence of clinical seizures without neurophysiological
confirmation is associated with worse outcomes at 4
years of age when the severity of MRI abnormalities is
controlled for [45]. Larger studies, however, have shown
the association between the presence of seizures and
outcome is complex [46–48]. One group found there is
no clear link between the presence of seizures and out-
come in HIE, but there is an association between in-
creasing seizure frequency and duration and outcome
[46]. A large retrospective cohort study using a national
insurance database found that neonatal seizures are
associated with greater risk of epilepsy and intellectual
disability later in life, independent of the aetiology of the
neonatal seizures [48]. None of these studies show con-
clusively that aggressive treatment of neonatal electrical
seizures improves outcome.
Another explanation why neonatologists are more
likely than neurologists to treat electrical seizures ag-
gressively relates to the aetiologies they see: neonatolo-
gists commonly see acute symptomatic seizures, so anti-
convulsant drug use is short-lived and within the realm
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of neuroprotection. Neurologists see more refractory
neonatal seizure, epilepsy, and a wider range of seizure
types and aetiologies, so treatment is more likely to be
unsuccessful, of longer duration, and with greater risk of
side effects. The published literature on whether short
term anti-convulsant drug use is harmful to neonates is
controversial: anti-convulsant drugs are associated with
neuronal apoptosis and inhibited neurogenesis in animal
models [49, 50] but little is known about this relationship
in humans. Levetiracetam and topiramate are less impli-
cated [51, 52], and topiramate may be neuroprotective
[53, 54]. A single retrospective study found increasing
doses of phenobarbital for neonatal seizures is associated
with worse cognitive outcome and cerebral palsy than
levetiracetam [55], and long-term treatment with pheno-
barbital in children with febrile convulsions is associated
with cognitive difficulties [56, 57].
When neonatal seizures do have clinical features, there is
variation in when consultants commence anti-convulsant
treatments: neonatologists who think seizures cause harm
treat them aggressively; others wait until the baby has had
“enough” seizures to warrant treatment. The timeframe for
this decision is entirely arbitrary and relates to dogmatic
rules consultants were taught as trainees. When a decision
is made to treat neonatal seizures, the choice of first line
drug is almost always phenobarbital because of familiarity
and tradition. Published evidence shows that phenobarbital
stops between 28 and 63% of neonatal seizures [11, 58–61],
so all neonatologists have seen it work and feel comfortable
with its side effects. The downside of this approach is that
it stops neonatologists gaining experience of other drugs
and, on the rare occasions they do use alternatives, it is as
second or third-line treatment in naturally more refractory
seizures. Neonatologists feel they cannot unilaterally change
their first-line drug choice because they worry about what
their colleagues would think if they broke with ingrained,
guideline-driven practice. Some neonatologists look to-
wards neurologists for their experience of alternative drugs
and want a national discussion to share experiences and
reach a consensus on drug treatment.
Neurologists have greater experience of a wide range
of drugs, and choose their first line treatment based on
seizure type and aetiology; for example, epileptic spasms
are treated with steroids and / or vigabatrin and tonic
seizures related to benign familial neonatal seizures with
carbamazepine. For acute symptomatic seizures, neurol-
ogists also choose phenobarbital first because of trad-
ition, but are more comfortable than neonatologists
using newer drugs, like levetiracetam. We found genuine
equipoise in both groups on whether Levetiracetam or
Phenobarbital is more effective, although neurologists
are more likely to report Levetiracetam as less effective,
perhaps reflecting the aetiologies they see. Reassuringly,
few reported side effects are seen with Levetiracetam, as
nearly 80% of questionnaire responders reporting Leve-
tiracetam had either no or mild side effects, reflecting
similar data from small studies [55, 60–66]. Inter-
viewees report they would like to change their first line
treatment to Levetiracetam if it was found to be equally
as effective as phenobarbital with less side effects, be-
cause phenobarbital’s sedative properties may prolong
hospital stays.
We found extreme variation in the choice and dosage
of second-line, third-line and subsequent drugs for neo-
natal seizures. Our interviews reveal that consultants do
not know which drugs are the most effective and rely on
the local traditions and network guidelines that often
reflect the personal preference of their local expert. Both
specialities report the need larger-scale studies into seiz-
ure treatments, but acknowledge their methodology and
logistics are problematic.
Finally, neurologists in our study reported they want
closer collaboration with neonatologists to share know-
ledge and experience. Neonatologists are more focussed
on working in neonatal networks, and only the inter-
viewees who had close liaison with neurology colleagues
saw the value of closer relationships. Currently, services
appear disparate. Promoting training and collaboration
between the two specialisms could improve care for neo-
nates, drive forward developments in education, and
help standardise care across the UK. An alternative
model could be the formation of Neonatal Neurology In-
tensive Care Units [67], but it remains to be seen if this
is the optimal method of delivering care in the UK given
large numbers of neonates are at risk of neurological
complications.
There are limitations to our data. Our response rate
for the questionnaire is reasonable, but there is no way
to determine whether the views and practices of individ-
uals who responded are the same as those who did not.
Some responders worked in the same units as others,
and it is possible that the culture of specific units where
multiple questionnaires were returned influenced the
interpretation of our questionnaire results. We only
interviewed consultants because the decision to investi-
gate and treat ultimately resides with them, but the
views of junior medical and nursing staff are important
as they are “first-line” when recognising abnormal move-
ments and seizures. We would have need a larger sample
size to reach data saturation as the range of views would
have been larger, and we did not have the resources to
do this. It is a potential future area of research to deter-
mine if the views of consultants are substantially differ-
ent from other members of staff. We also acknowledge
that the responders to our questionnaire in Phase one
were from a mixture of staff members, so the data from
Phase One may not be directly transferable to the results
of our interviews. However, 81.0% of questionnaire
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responders were consultants, so the effect of having
other health care professionals answer the questionnaire
is likely to be small. We purposefully chose consultants
from different units, specialities, sex and experience
levels to obtain as wide a range of their views as possible,
but we cannot comment on the views of consultants
who did not volunteer to be interviewed. Therefore, as
with any qualitative interview study, we cannot guaran-
tee our results are generalisable to all consultants
managing neonatal seizures. Finally, we are aware that
medicine, where possible, should be evidence-based.
There are many limitations to relying on clinicians’ per-
ceptions of what they think they do, which can be very
different from their practice in real life, and the effect-
iveness of drug therapies. However, understanding per-
ceptions is important because they explain why some
people follow (or not) evidence and guidelines, and why
clinicians make the choices they do when evidence is
limited or of poor quality, as with the treatments of neo-
natal seizures. Where good quality exists, it is important
it is followed because perceptions may be wrong.
Conclusion
Health care professionals face many uncertainties when
diagnosing, investigating and treating neonatal seizures,
resulting in wide variations in practice throughout the
UK. Our data is the first to reveal the views of paediatri-
cians and the challenges they face, along with the solu-
tions they suggest. These include: development of
nationwide educational packages to improve the descrip-
tions taken of neonatal seizures and aEEG interpretation;
increased use of video; improved access to neurophysi-
ology investigations; a national discussion on whether
aEEG should be available in level 2 units or if evaluation
of all neonates with suspected seizures should be centra-
lised to level 3 units; and closer collaboration between
neurology and neonatal teams to drive forward a na-
tional consensus guideline, which would standardise the
management of neonatal seizures across the UK.
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